Mepivacaína B. Braun

Mepivacaine, the active ingredient in Mepivacaína B. Braun, is a local anesthetic presented as a sterile solution for epidural, intradermal and perineural use. It provides reversible loss of sensation in targeted nerve regions for surgical and diagnostic procedures. GNH USA supplies Mepivacaína B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mepivacaine is used in clinical settings to achieve local anesthesia through various administration routes. - Epidural anesthesia: produces a dense block of sensation for obstetric or lower‑body surgeries. - Intradermal anesthesia: provides rapid, superficial numbness for minor skin procedures and diagnostic testing. - Perineural anesthesia: creates targeted nerve block to facilitate orthopedic or dental surgeries.

Mepivacaine may cause a range of adverse reactions, most of which are dose‑related and transient.

Common Side Effects: - Mild hypotension: temporary drop in blood pressure after injection. - Dizziness or light‑headedness: sensation of unsteadiness during onset. - Nausea or vomiting: gastrointestinal upset in some patients. - Transient metallic taste: brief alteration in taste perception. - Injection site pain or burning: local discomfort at the puncture site. - Tingling or numbness beyond the intended area: mild paresthesia.

Serious or Rare Side Effects: - Cardiovascular collapse: severe drop in heart function requiring emergency care. - Anaphylaxis: life‑threatening allergic reaction with rash, swelling, and airway compromise. - Seizures: central nervous system excitation in overdose situations. - Prolonged nerve block: extended loss of motor function beyond expected duration. - Methemoglobinemia: abnormal hemoglobin causing reduced oxygen delivery. - Cardiac arrhythmia: irregular heart rhythm potentially leading to hemodynamic instability.

When using Mepivacaína B. Braun, clinicians should observe several safety measures. - Patient assessment: evaluate cardiovascular and hepatic status before administration. - Dose adjustment: reduce dose in patients with impaired liver function. - Allergy screening: avoid use in individuals with known hypersensitivity to amide‑type anesthetics. - Cardiovascular monitoring: observe heart rate and blood pressure during and after injection. - Concomitant anesthetics: limit simultaneous use of other local anesthetics to prevent toxicity. - Store at ambient temperature: keep in original packaging, protect from moisture and direct light.

Mepivacaine can interact with other drugs, altering its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): increase risk of cardiac toxicity. - High‑dose epinephrine: may exacerbate cardiovascular effects. - Other amide local anesthetics: additive neuro‑ and cardiotoxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise plasma levels. - Beta‑blockers: enhance bradycardia and hypotension. - Diuretics: potentiate hypotensive response.